Victor Gerber , Louis Boehn , Marcela Sabou , Antoine Studer , Axel Ursenbach , Yves Hansmann , Raoul Herbrecht , Nicolas Lefebvre , Valérie Letscher-Bru , François Danion
{"title":"Is there an interest in systematic serum screening for aspergillosis in COVID-19 patients in a medical ward?","authors":"Victor Gerber , Louis Boehn , Marcela Sabou , Antoine Studer , Axel Ursenbach , Yves Hansmann , Raoul Herbrecht , Nicolas Lefebvre , Valérie Letscher-Bru , François Danion","doi":"10.1016/j.idnow.2024.104918","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>We evaluated the interest of systematic screening of serum fungal markers in patients hospitalized in a medical ward.</p></div><div><h3>Methods</h3><p>We retrospectively analyzed all patients hospitalized in our infectious disease department from October 1st to October 31st, 2020 for COVID-19 without prior ICU admission, and for whom systematic screening of serum fungal markers was performed.</p></div><div><h3>Results</h3><p>Thirty patients were included. The majority of patients received corticosteroids (96.7%). The galactomannan antigen assay was positive for 1/30 patients at D0, and 0/24, 0/16, 0/13 and 0/2 at D4, D7, D10 and D14 respectively. 1,3-ß-D-glucan was positive for 0/30, 1/24, 1/12, 0/12, 0/2 at D0, D4, D7, D10 and D14 respectively. No <em>Aspergillus fumigatus</em> PCR was positive. No cases of aspergillosis were retained.</p></div><div><h3>Conclusion</h3><p>Our study does not support the interest of systematic screening of fungal markers in immunocompetent patients with COVID-19 in a conventional unit.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 4","pages":"Article 104918"},"PeriodicalIF":2.9000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924000757/pdfft?md5=6625c2ae90df49374a4facefa0017fee&pid=1-s2.0-S2666991924000757-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases now","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666991924000757","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
We evaluated the interest of systematic screening of serum fungal markers in patients hospitalized in a medical ward.
Methods
We retrospectively analyzed all patients hospitalized in our infectious disease department from October 1st to October 31st, 2020 for COVID-19 without prior ICU admission, and for whom systematic screening of serum fungal markers was performed.
Results
Thirty patients were included. The majority of patients received corticosteroids (96.7%). The galactomannan antigen assay was positive for 1/30 patients at D0, and 0/24, 0/16, 0/13 and 0/2 at D4, D7, D10 and D14 respectively. 1,3-ß-D-glucan was positive for 0/30, 1/24, 1/12, 0/12, 0/2 at D0, D4, D7, D10 and D14 respectively. No Aspergillus fumigatus PCR was positive. No cases of aspergillosis were retained.
Conclusion
Our study does not support the interest of systematic screening of fungal markers in immunocompetent patients with COVID-19 in a conventional unit.